Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Company Logo

Destroying Cancer at the Speed of Light®

Clinical Study Underway (68 of 100 Patients Treated)
Expected to complete enrollment at the end of 2024
Expected to complete study at the end of 2026


Bullboard - Investor Discussion Forum Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  V.TLT.WT | TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called... see more

TSXV:TLT - Post Discussion

Theralase Technologies Inc. > Repost of Speculative Share Price
View:
Post by 99942Apophis on Nov 29, 2021 9:26pm

Repost of Speculative Share Price

This will hopefully play out after a major number of patients have been treated. Post from a couple of weeks ago.


Ok skys1 let's look at PE ( the share price to earnings ratio), I see you use an estimate of 300,000,000 shares to an estimated 3 billion offer to buyout the company equals $10.00. So in an established listed senior stock they have roughly a PE ratio of 20 to 25 lets use both to see what that actual individual share price would be, take $10.00 ÷ 20 = $0.50 profit a share or $10.00 ÷ 25 = $0.40 profit a share. Perhaps you know how PE works but some don't and what it means is if TLT'S yearly net profit was $0.40 and it was a slow earning senior company it could be awarded a PE multiple of 25 for that 40 cents which comes out to $10.00.
In a previous post I projected a theoretical profit! If Theralase were in its first year for only profits on NMIBC. So first year TLT might get 10% of the estimated 96,000 bladder patients from only Canada & US (ignoring the possible profit from the rest of the world) so 9,600 is 10% X 50,000 a patient or 100,000 or 150,000? Let's use 50K that comes to $480,000,000 now let's say cost to the company to earn that amount was $280,000,000 so net profit is 200 million ( all fictitious numbers ) so 200 million divided by total shares of 300 million is $0.67 profit for each share with even a low PE ratio of 20 we get $13.40. I would think if they do well they will be awarded a speculative PE ratio of 50 ( $33.50 ) or 75 ( $50.25 ).
My argument against a 3 billion buyout is the hugh profit capability of this company and in my biased opinion $10.00 is a slap in the face.
Comment by skys1 on Nov 30, 2021 8:21am
Apophis, I agree with all your figures. The point I was trying to make is that because of the money, power, & influence of Big Pharma they are going to want this not only for the worldwide profit potential a cure for cancer could bring, but their current $billions in revenue will disdsapear if they don't make a move. So the question is will Big Pharma use it's clout to gobble up TLT or ...more  
Comment by 99942Apophis on Nov 30, 2021 9:10am
Hi skys1 that has also been on my mind too we can only hope some sort of franchise agreement will be reached with Theralase for all the large world Pharmaceutical companies. If an arrangement can't be reach we could witness a very ugly multi Pharmaceutical price war amongst themselves as to who will win.Ugly war for them really good for Theralase's shareholders. Then of course the other ...more  
Comment by blackjack0 on Nov 30, 2021 9:24am
And when the market finally realize that this treatment will work the same on other indications the potential is enormous. Not to forget they have a potentially much better alternative in TLD1633
Comment by menoalittle on Nov 30, 2021 9:29am
mmmm.... maybe for the heck of it me buys a couple k more at the open to help give it a little wake up kick in the buttocks... lol.
Comment by menoalittle on Nov 30, 2021 9:36am
my goodness... appears it certainly didn't need any of my help jumping right out of bed this morning! yea! run, baby, run.
Comment by Lesalpes29 on Nov 30, 2021 9:49am
Bought at .27 to average up! I really prefer this way!
Comment by Rumpl3StiltSkin on Nov 30, 2021 10:04am
Nice!! :-)
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.TLT



Investor Presentation

View the Presentation

FACT SHEET

View the Presentation

The Watchlist

The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

The Road to Saving Lives: Clinical Study Underway

  • Clinical Study with 68 of 100 Patients Treated (Enrollment to be completed by end of 2024, with study completed by end of 2026)
     
  • Ground Floor Investment Opportunity in Multi-Billion Dollar Industry
     
  • Best-in-class treatment for NMIBC (according to interim clinical data)
     
  • NMIBC (Non-Muscle-Invasive Bladder Cancer)
     

Facebook

Contact Us

Address:
41 Hollinger Road
Toronto, ON M4B 3G4
Canada

Toll Free:
1-866-THE-LASE (843-5273)
Local Phone:
416-699-LASE (5273)

Email:
info@theralase.com

Fax:
416-699-5250